



CENTER FOR MEDICARE

DATE: April 15, 2022

TO: All Prescription Drug Plans, Medicare Advantage- Prescription Drug Plans, and Medicare-Medicaid Plans

FROM: Amy Larrick Chavez-Valdez, Director
Medicare Drug Benefit and C & D Data Group

SUBJECT: Contract Year 2023 Medication Therapy Management Program Information and Submission Instructions

This memorandum provides information to Part D sponsors regarding contract year (CY) 2023 Medication Therapy Management (MTM) programs. New and renewing Medicare Advantage Prescription Drug Plans (MA-PDs), stand-alone Prescription Drug Plans (PDPs), and Medicare-Medicaid Plans (MMPs) may rely on the August 31, 2021 HPMS memorandum “Correction to Contract Year 2022 Part D Medication Therapy Management Program Guidance and Submission Instructions dated April 30, 2021”, which can be found on the CMS Part D MTM webpage at <https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/MTM>, in addition to the information provided in this memorandum.

Important Dates for 2023 MTM Program Submissions and Attestations

The 2023 deadlines are as follows. These dates were also included in the February 3, 2022 memorandum titled, “Contract Year (CY) 2023 Final Part D Bidding Instructions”.

Action	Date
Release of the CY 2023 MTM Program submission module in HPMS (12:01 a.m. EDT).	May 9, 2022
Deadline for submission of CY 2023 MTM Programs in HPMS (11:59 p.m. PDT).	May 23, 2022
Deadline for submission of CY 2023 MTM Program attestations in HPMS (11:59 pm PDT).	June 6, 2022

A technical user’s manual titled, HPMS CY 2023 MTM Program User’s Guide, will be available for download through the CY 2023 MTM Program Submission module under Documentation in HPMS on or around April 25, 2022.

Annual Eligibility Threshold

Per 42 C.F.R. § 423.153(d)(2)(i)(C)(2), for 2012 and subsequent years, the annual cost threshold for targeting beneficiaries is specified as costs for covered Part D drugs in an amount greater than or equal to \$3,000 increased by the annual percentage specified in 42 C.F.R. § 423.104(d)(5)(iv). The 2022 MTM program annual cost threshold is \$4,696. The 2023 MTM program annual cost threshold is determined by updating the 2022 MTM program annual cost threshold using the annual percentage increase of 5.08% as specified in the Announcement of Calendar Year (CY) 2023 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies dated April 4, 2022¹. Therefore, the 2023 MTM program annual cost threshold is \$4,935.

Standardized Format

An individualized, written summary in CMS' standardized format must be provided following each comprehensive medication review (CMR). The current standardized format and technical instructions are posted on the [CMS Part D MTM webpage](#). The standardized format for the CMR summary must be approved by the Office of Management and Budget (OMB) through the Paperwork Reduction Act (PRA) process. OMB has approved the current version of the standardized format (CMS-10396; OMB control number: 0938-1154) until February 29, 2024.

Electronic delivery

Per 42 C.F.R. § 423.2267(d)(2)(ii), Part D sponsors may provide any required material or content electronically with prior consent from the enrollee. This includes the CMR offer letter, targeted medication reviews (TMRs), the CMR Summary in the CMS' standardized format, and information about Safe Disposal of Controlled Substances. When delivering content electronically, Part D sponsors should be able to document the individual received the information.

Safe Disposal Information

Pursuant to 42 C.F.R. § 423.153(d)(1)(vii)(E), Part D sponsors must provide to all MTM enrollees, at least annually, information about safe disposal of prescription drugs that are controlled substances. Under 42 C.F.R. § 423.153(d)(1)(vii)(F), such enrollees must be provided all information required at 42 C.F.R. § 422.111(j), which includes both a link to the U.S. Drug Enforcement Administration (DEA) website at www.deatakeback.com and the location of two or more drug take back sites that are available in the community where the enrollee resides. Specifically, the identified drug take back sites must be among the drug take back sites that are generally utilized by people residing in the same community as the MTM enrollee. That is, drug take back sites that are physically located within the shortest travel times. While the identification of two drug take back sites available to the enrollee identifies multiple choices, we encourage plans to identify additional community take back sites. For additional information,

¹Available at: <https://www.cms.gov/medicarehealth-plansmedicareadvtspecratestatsannouncements-and-documents/2023>

refer to the January 19, 2021 Final Rule ([86 FR 5892-3](#)) titled “Medicare and Medicaid Programs; Contract Year 2022 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicaid Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly.”

The DEA includes on its website a text file, updated daily, containing the year-round drug disposal locations registered with the DEA. The file is available at <https://apps.dea diversion.usdoj.gov/pubdisp/>. Links to the file are also posted on the [National Prescription Drug Take Back Day website](#) and the DEA’s [Registration](#) page. Part D sponsors may use the DEA search engine and/or other resources to identify the two or more locations for the enrollee. The information should be accurate at the time the notice is developed and plans have the flexibility to tailor their language to aid in the beneficiary’s understanding. As with the CMR offer and CMR summary, safe disposal information that is sent and returned in the mail cannot be considered received.

For questions related to Part D MTM Programs, email PartD_MTM@cms.hhs.gov. If you have any questions on accessing the HPMS MTM Program Submission module, contact the HPMS Help Desk at 1-800-220-2028.